Corpus Intelligence IC Memo — WYOMING MEDICAL CENTER 2026-04-26 12:05 UTC
IC Memo — WYOMING MEDICAL CENTER
Investment Committee Memorandum | WY | 226 beds | Grade C | EBITDA uplift $16.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

WYOMING MEDICAL CENTER

CCN 530012 | NATRONA, WY | 226 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

WYOMING MEDICAL CENTER is a 226-bed suburban community hospital in NATRONA, WY with $227.9M in net patient revenue and a -2.7% operating margin. The hospital serves a payer mix of 47.9% Medicare, 4.2% Medicaid, and 47.8% commercial.

Thesis: Undervalued. Our ML models identify $16.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -2.7% to 4.7% (+736bps).

Net Revenue HCRIS$227.9M
Current EBITDA COMPUTED$-6.1M
Operating Margin COMPUTED-2.7%
Occupancy HCRIS44.5%
Revenue / Bed COMPUTED$1.0M
Net-to-Gross HCRIS34.3%
Distress Probability ML51.5%

2. Market Context & Competitive Position

29
WY Hospitals
-7.5%
State Median Margin
1808
Comparable Hospitals

WY has 29 Medicare-certified hospitals with a median operating margin of -7.5%. The target's margin of -2.7% places it above the state median. Among 1808 size-comparable peers (113-452 beds), the median margin is -3.8%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (113-452), prioritizing same-state peers. 1808 hospitals in the comp set.

HospitalStateBedsRevenueMargin
WYOMING MEDICAL CENTER (Target)WY226$227.9M-2.7%
RONALD REAGAN UCLACA446$2.62B-6.8%
LUCILE PACKARD CHILDRENS HOSPICA394$2.39B-0.8%
MAYO CLINIC HOSPITALAZ315$2.25B1.4%
RAINBOW BABIES & CHILDRENS HOSOH231$2.22B-5.0%
EASTERN MAINE MEDICAL CENTERME352$2.05B48.1%
ARTHUR G JAMES CANCER HOSPITALOH356$1.95B21.0%
MOFFITT CANCER CENTERFL218$1.91B16.0%
UCI MEDICAL CENTERCA397$1.90B-2.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $16.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$4.8M+210bp18mo
Cost to Collect4.5%2.5%$4.6M+200bp12mo
Denial Rate Reduction12.0%6.5%$4.5M+198bp12mo
A/R Days Reduction5200.0%3800.0%$2.8M+122bp9mo
Clean Claim Rate88.0%96.0%$146K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$4.8M
Cost to Collect
$4.6M
Denial Rate Reduction
$4.5M
A/R Days Reduction
$2.8M
Clean Claim Rate
$146K
Total EBITDA Uplift$16.8M
Current EBITDA$-6.1M
+ RCM Uplift+$16.8M
Pro Forma EBITDA$10.6M
Current Margin-2.7%
Pro Forma Margin4.7%
WC Released (1x)$8.7M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-9.5M$127.2M0.00x-100.0%
Base (11x exit)10.0x11.0x$-9.5M$136.9M0.00x-100.0%
Bull Case9.0x11.0x$-8.5M$189.2M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-8.5M$203.9M0.00x-100.0%
Bear Case11.0x10.0x$-10.4M$46.4M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-10.4M$47.7M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 51.5% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 1808 hospitals with 113-452 beds
  • Same-state prioritization (n=3)
  • Comp margins: P25=-13.7% / P50=-3.8% / P75=6.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.